Pharmaceuticals, Biotechnology and Life Sciences
Results include first U.S. revenue from Gleolan, full commercial launch expected in fiscal Q2 Treosulfan NDA resubmitted to the FDA,…
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile —…
Data from the Phase 3 SPIRIT program showed MYFEMBREE reduced menstrual pain and non-menstrual pelvic pain in premenopausal women with…
THE WOODLANDS, Texas, Aug. 05, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the issuance and…
PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a…
Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical…
— Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing — — Cash runway…
BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class…
Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategyCAMBRIDGE, Mass., Aug.…
Reported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results…